SHSE:688166's Quick Ratio is ranked worse than 66.03% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs SHSE:688166: 1.97
Brightgene Bio-medical Technology Co (SHSE:688166) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Brightgene Bio-medical Technology Co Quick Ratio Related Terms
Brightgene Bio-medical Technology Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co Quick Ratio Chart
SHSE:688166 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brightgene Bio-medical Technology Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Brightgene Bio-medical Technology Co's Quick Ratio falls into.
Brightgene Bio-medical Technology Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Quick Ratio of 1.97 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Brightgene Bio-medical Technology Co and its competitors. This is near median its historical median of 1.80. Over the past decade, Brightgene Bio-medical Technology Co's Quick Ratio has ranged from 0.89 to 9.10. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #931 out of 1410 companies in the Biotechnology industry, placing it in the top 66%.
Is Brightgene Bio-medical Technology Co's Quick Ratio too high?
Brightgene Bio-medical Technology Co's current Quick Ratio of 1.97 is near median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 9.10. The Biotechnology industry median Quick Ratio is 3.60. Brightgene Bio-medical Technology Co's value of 1.97 is 45.3% below this industry median. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #931 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #931 out of 1410 companies for Quick Ratio. This places Brightgene Bio-medical Technology Co in the lower half of its industry. The industry median Quick Ratio is 3.60. Brightgene Bio-medical Technology Co's value of 1.97 is 45.3% below this benchmark. Historically, Brightgene Bio-medical Technology Co's own Quick Ratio has ranged from 0.89 to 9.10 over the past decade. While the company's 10-year median is 1.80 vs. the industry median of 3.60, Brightgene Bio-medical Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brightgene Bio-medical Technology Co's current Quick Ratio of 1.97 is 45.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Brightgene Bio-medical Technology Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brightgene Bio-medical Technology Co's current Quick Ratio is 1.97, which is near median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Quick Ratio is 1.97, which is near median its 10-year median of 1.80 and 45.3% below the Biotechnology industry median of 3.60. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Quick Ratio is 1.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Quick Ratio: 1.97 (near median its 10-year median of 1.80)
GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
Industry Position: 45.3% below the Biotechnology median (#931 of 1410)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
